Regeneron Announces Promising Five-Year Results for Libtayo in Advanced Non-Small Cell Lung Cancer, Doubling Overall Survival Rates
Reuters
Sep 09
Regeneron Announces Promising Five-Year Results for Libtayo in Advanced Non-Small Cell Lung Cancer, Doubling Overall Survival Rates
Regeneron Pharmaceuticals, Inc. has announced five-year follow-up results from the Phase 3 EMPOWER-Lung 3 trial, evaluating Libtayo® (cemiplimab) in combination with platinum-based chemotherapy as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) without EGFR, ALK, or ROS1 aberrations. The results, which have already been presented at the IASLC 2025 World Conference on Lung Cancer, demonstrate that the combination treatment more than doubles the five-year overall survival rate to 19.4%, compared to 8.8% with chemotherapy alone. The study showed consistent efficacy across histologies, with a notable median overall survival of 22.3 months for the squamous patient population. Additionally, exploratory subgroup analyses indicated survival benefits regardless of tumor histology or PD-L1 expression levels.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9525513-en) on September 09, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.